Back to Directory

Denosumab

Performance & Endurance

RANKL inhibitor monoclonal antibody for osteoporosis and bone metastases.

Key Benefits

  • ✓Increases bone density
  • ✓Reduces fracture risk
  • ✓Convenient twice-yearly dosing
  • ✓For osteoporosis and cancer bone mets
  • ✓Potent antiresorptive

Dosing Information

Dosage Range
60-120 mg
Frequency
Every 6 months or monthly
Typical Duration
Ongoing

Detailed Protocol

Administered via subcutaneous injection every 6 months for osteoporosis (Prolia 60mg) or monthly for cancer (Xgeva 120mg). Must ensure adequate calcium/vitamin D. Prescription only.

About Denosumab

Denosumab (Prolia, Xgeva) is a human monoclonal antibody that inhibits RANKL, preventing osteoclast formation and bone resorption. FDA-approved for osteoporosis (Prolia) and prevention of skeletal-related events in cancer (Xgeva).

Research Notes

FDA-approved 2010 (Prolia) for osteoporosis. Convenient twice-yearly dosing. Potent bone protection. Concerns about stopping (rebound fractures) require transition plan. Calcium supplementation essential.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Back pain
  • •Muscle pain
  • •Hypocalcemia risk
  • •Osteonecrosis of jaw (rare)
  • •Atypical fractures with long-term use
  • •Rebound vertebral fractures if stopped

Always consult with a healthcare professional before starting any peptide therapy.